LAUSANNE, Switzerland, May 17, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Dr. Andrea Pfeifer, CEO and a Director of AC Immune, will be awarded the prestigious Aenne Burda Award for Creative Leadership at the 22nd DLD Conference to be held in Munich, Germany, May 20-22, 2022.
Martin Weiss, CEO of Hubert Burda Media, commented: “Aenne Burda, was a trailblazing role model for women at a time when they were first emerging as professional leaders. We are honoring Dr. Andrea Pfeifer, with this award which recognizes her leadership as CEO and Founder of AC Immune, and her pioneering work, determination, and influence in the field of neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, which have profound health, social and economic impacts on our global society.”
Prof. Monika Bütler, Member of the Board of Directors at AC Immune said: “We are proud that our CEO, Andrea Pfeifer, will receive this prestigious award. She is a globally recognized strategic leader, opinion maker and catalyst in the challenging field of neurodegenerative diseases, and a source of inspiration to us all. Most importantly, we welcome this influential award as an act of advocacy to support efforts worldwide to address the global pandemic of neurodegenerative disease with urgency.”
The Aenne Burda Award for Creative Leadership stands for courage, creativity, optimism, and the uncompromising belief in realizing creative goals. These attributes distinguished Aenne Burda as a female entrepreneur who is a source of inspiration for women of all generations. It is the first time a leader in Biotechnology will be honored with this award.
During the award ceremony, Dr. Pfeifer will be recognized for her role in developing AC Immune, a company she has led since 2003, into a global pioneer of new diagnostics and treatments for neurodegenerative diseases, including Alzheimer’s and Parkinson’s diseases. Neurodegenerative diseases are a silent, worldwide pandemic which increasingly impact health, lifestyle and global economics.
In leading AC Immune, Dr. Pfeifer has overseen the integration of deep scientific knowledge, cutting-edge technology platforms and industrial drug development capabilities, enabling development of one of the largest and most promising pipelines focused on neurodegenerative diseases in the industry, including multiple investigational vaccines, antibodies, small molecule drugs and diagnostic agents. Her global influence and dedication in the search for treatments for neurogenerative disease are widely acknowledged.
About AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen® and Morphomer®, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features ten therapeutic and three diagnostic candidates, six of which are currently in clinical trials. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies including Genentech, a member of the Roche Group, Eli Lilly and Company, and Janssen Pharmaceuticals, Inc., resulting in substantial non-dilutive funding to advance its proprietary programs and >$3 billion in potential milestone payments.
SupraAntigen® is a registered trademark of AC Immune SA in the following territories: AU, EU, CH, GB, JP, RU and SG. Morphomer® is a registered trademark of AC Immune SA in CN, CH, GB, JP, NO and RU.
For further information, please contact:
Forward looking statements
This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. These include: the impact of Covid-19 on our business, suppliers, patients and employees and any other impact of Covid-19. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.
Source: AC Immune SA